Informaciones Psiquiátricas 2024 - n.º 253 93 54. Rodrigues-dos-Santos M, Bhasin S. Benefits and risks of testosterone treatment in men with age-related decline in testosterone. Annu Rev Med. 2021; 72:75–91. doi: 10.1146/ annurev-med-050219-034711 55. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone therapy in men with hypogonadism: An Endocrine Society Clinical practice guideline. J Clin Endocrinol Metab. 2018; 103(5):1715– 44. doi: 10.1210/jc.2018-00229 56. Jaspers L, Feys F, Bramer WM, Franco OH, Leusink P, Laan ET. Efficacy and safety of Flibanserin for the treatment of hypoactive sexual desire disorder in women: A systematic review and meta-analysis. JAMA Intern Med. 2016; 176(4):453–62. doi: 10.1001/jamainternmed.2015.8565 57. Clayton AH, Pyke RE. Is Flibanserin meaningfully superior to placebo? J Sex Marital Ther. 2017; 43(3):218–22. doi: 10.1080/0092623X.2017.1280865. Erratum in: J Sex Marital Ther. 2017 Nov 2;1. 58. Kingsberg SA, McElroy SL, Clayton AH. Evaluation of Flibanserin safety: Comparison with other serotonergic medications. Sex Med Rev. 2019; 7(3):380–92. doi: 10.1016/j. sxmr.2018.12.003 59. Schön V, Hengartner MP, Tronci E, Mancini T, Ille F, Röblitz S, et al. Sexual attraction to visual sexual stimuli in association with steroid hormones across menstrual cycles and fertility treatment. Psychoneuroendocrinology. 2023; 151:106060. doi: 10.1016/j. psyneuen.2023.106060 60. Marko KI, Simon JA. Androgen therapy for women after menopause. Best Pract Res Clin Endocrinol Metab. 2021; 35(6):101592. doi: 10.1016/j. beem.2021.101592 61. Parish SJ, Simon JA, Davis SR, Giraldi A, Goldstein I, Goldstein SW, et al. International society for the study of women's sexual health clinical practice guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women. J Sex Med. 2021; 18(5):849–67. doi: 10.1016/j. jsxm.2020.10.009 62. Uloko M, Rahman F, Puri LI, Rubin RS. The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: A review. Int J Impot Res. 2022; 34(7):635–41. doi: 10.1038/s41443-022-00613-0 63. Corona G, Rastrelli G, Bianchi N, Sparano C, Sforza A, Vignozzi L, et al. Hyperprolactinemia and male sexual function: Focus on erectile dysfunction and sexual desire. Int J Impot Res. 2023. doi: 10.1038/ s41443-023-00717-1 64. Pfaus JG, Antonie RA, Dosa PI, Kim SW. Effects of cabergoline and dimethylcabergoline on the sexual behavior of male rats. Psychopharmacology (Berl). 2023. doi: 10.1007/ s00213-023-06501-9 AMOR, DESEO, SEXUALIDAD Y SALUD MENTAL
RkJQdWJsaXNoZXIy MzkyOTU=